The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
Open accessAbstract
BACKGROUND & AIMS: The Sorafenib Hepatocellular Carcinoma (HCC) Assessment Randomized Protocol (SHARP) trial demonstrated that sorafenib improves overall survival and is safe for patients with advanced HCC. In this trial, 602 patients with well-preserved liver function (>95% Child-Pugh A) were randomized to receive either sorafenib 400mg or matching placebo orally b.i.d. on a continuous basis. Because HCC is a heterogeneous disease, baseline patient characteristics may affect individual responses to treatment. In a comprehensive series of exploratory subgroup analyses, data from the SHARP trial were analyzed to discern if baseline patient characteristics influenced the efficacy and safety of sorafenib. METHODS: Five subgroup domains were assessed: disease etiology, tumor burden, performance status, tumor stage, and prior therapy. Overall survival (OS), time to progression (TTP), disease control rate (DCR), and safety were assessed for subgroups within each domain. RESULTS: Subgroup analyses showed that sorafenib consistently improved median OS compared with placebo, as reflected by hazard ratios (HRs) of 0.50-0.85, similar to the complete cohort (HR=0.69). Sorafenib also consistently improved median TTP (HR, 0.40-0.64), except in HBV-positive patients (HR, 1.03), and DCR. Results are limited by small patient numbers in some subsets. The most common grade 3/4 adverse events included diarrhea, hand-foot skin reaction, and fatigue; the incidence of which did not differ appreciably among subgroups. CONCLUSIONS: These exploratory subgroup analyses showed that sorafenib consistently improved median OS and DCR compared with placebo in patients with advanced HCC, irrespective of disease etiology, baseline tumor burden, performance status, tumor stage, and prior therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationManagement of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,103
Self-citationCheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Self-citationSorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
El–Serag, H. B., & Rudolph, K. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.061 · Cited by 5,415
Forner, A., Llovet, J. M., & Bruix, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61347-0 · Cited by 4,022
Self-citationWilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification
Llovet, J., Brú, C., & Bruix, J. (1999) · Seminars in Liver Disease · doi:10.1055/s-2007-1007122 · Cited by 3,805
Self-citationHepatocellular carcinoma in cirrhosis: Incidence and risk factors
Fattovich, G., Stroffolini, T., Zagni, I., & Donato, F. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.014 · Cited by 2,591
Hepatocellular carcinoma pathogenesis: from genes to environment
Farazi, P. A., & DePinho, R. A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1934 · Cited by 1,979
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2130 · Cited by 1,829
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
Llovet, J. M., Di Bisceglie, A. M., Bruix, J., Kramer, B. S., Lencioni, R., Zhu, A. X., Sherman, M., Schwartz, M., Lotze, M., Talwalkar, J., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn134 · Cited by 1,653
Self-citationImamura, H., Matsuyama, Y., Tanaka, E., Ohkubo, T., Hasegawa, K., Miyagawa, S., Sugawara, Y., Minagawa, M., Takayama, T., Kawasaki, S., et al. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00360-4 · Cited by 1,589
A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients
(1998) · Hepatology · doi:10.1002/hep.510280322 · Cited by 1,238
Llovet, J. M., Bustamante, J., Castells, A., Vilana, R., Del Carmen Ayuso, M., Sala, M., Brú, C., Rodés, J., & Bruix, J. (1999) · Hepatology · doi:10.1002/hep.510290145 · Cited by 1,190
Self-citationEpidemiology of Primary Liver Cancer
Bosch, F., Ribes, J., & Borràs, J. (1999) · Seminars in Liver Disease · doi:10.1055/s-2007-1007117 · Cited by 958
American Association for the Study of Liver Diseases
Popper, H. (1960) · Gastroenterology · doi:10.1016/s0016-5085(60)80094-7 · Cited by 903
Novel advancements in the management of hepatocellular carcinoma in 2008
Llovet, J. M., & Bruix, J. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.01.022 · Cited by 815
Self-citationMarkou, K. D., Nikolaou, A. C., & Themelis, C. (2011) · Cited by 757
Kudo, M., Chung, H., & Osaki, Y. (2003) · Journal of Gastroenterology · doi:10.1007/s005350300038 · Cited by 700
Simplified Staging for Hepatocellular Carcinoma
Vauthey, J. N., Lauwers, G. Y., Esnaola, N. F., Do, K.-A., Belghiti, J., Mirza, N., Curley, S. A., Ellis, L. M., Regimbeau, J.-M., Rashid, A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1527 · Cited by 700
Donato, F. (2002) · American Journal of Epidemiology · doi:10.1093/aje/155.4.323 · Cited by 677
Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort†
Marrero, J. A., Fontana, R. J., Barrat, A., Askari, F., Conjeevaram, H. S., Su, G. L., & Lok, A. S. (2005) · Hepatology · doi:10.1002/hep.20636 · Cited by 637
Self-citationLeung, T. W. T., Tang, A. M. Y., Zee, B., Lau, W. Y., Lai, P. B. S., Leung, K. L., Lau, J. T. F., Yu, S. C. H., & Johnson, P. J. (2002) · Cancer · doi:10.1002/cncr.10384 · Cited by 583
Associations Between Hepatitis B Virus Genotype and Mutants and the Risk of Hepatocellular Carcinoma
Yang, H.-I., Yeh, S.-H., Chen, P.-J., Iloeje, U. H., Jen, C.-L., Su, J., Wang, L.-Y., Lu, S.-N., You, S.-L., Chen, D.-S., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn243 · Cited by 580
(2000) · Hepatology · doi:10.1053/he.2000.5628 · Cited by 521
A new prognostic classification for predicting survival in patients with hepatocellular carcinoma
Chevret, S., Trinchet, J.-C., Mathieu, D., Rached, A. A., Beaugrand, M., & Chastang, C. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80173-1 · Cited by 512
Self-citationPerformance status assessment in cancer patients. An inter-observer variability study
Sørensen, J., Klee, M., Palshof, T., & Hansen, H. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.140 · Cited by 483
BAY 43-9006 Inhibition of Oncogenic RET Mutants
Carlomagno, F., Anaganti, S., Guida, T., Salvatore, G., Troncone, G., Wilhelm, S. M., & Santoro, M. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj069 · Cited by 476
Cabibbo, G., Enea, M., Attanasio, M., Bruix, J., Craxì, A., & Cammà, C. (2010) · Hepatology · doi:10.1002/hep.23485 · Cited by 473
Self-citationPoon, D., Anderson, B. O., Chen, L.-T., Tanaka, K., Lau, W. Y., Van Cutsem, E., Singh, H., Chow, W. C., Ooi, L. L., Chow, P., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70241-4 · Cited by 410
Performance status assessment in cancer patients
Conill, C., Verger, E., & Salamero, M. (1990) · Cancer · doi:10.1002/1097-0142(19900415)65:8<1864::aid-cncr2820650832>3.0.co;2-u · Cited by 361
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Jelic, S., & Sotiropoulos, G. C. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq166 · Cited by 228
Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma
Kane, R. C., Farrell, A. T., Madabushi, R., Booth, B., Chattopadhyay, S., Sridhara, R., Justice, R., & Pazdur, R. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0185 · Cited by 221
World Gastroenterology Organisation Guideline. Hepatocellular carcinoma (HCC): a global perspective.
Ferenci, P., Fried, M., LaBrecque, D. R., Bruix, J., Sherman, M., Omata, M., Heathcote, J., Piratsivuth, T., Kew, M., Otegbayo, J. A., et al. (2010) · PubMed · Cited by 169
Self-citationNatural History of Untreated Nonsurgical Hepatocellular Carcinoma
Yeung, Y. P., Lo, C. M., Liu, C., Yu, W. B. C., Fan, S. T., & Wong, J. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.00229.x · Cited by 146
Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC).
Cheng, A., Kang, Y., Lin, D., Park, J., Kudo, M., Qin, S., Omata, M., Lowenthal, S. W. P., Lanzalone, S., Yang, L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.4000 · Cited by 118
Assessment of Patient-Reported Clinical Outcome in Pancreatic and Other Hepatobiliary Cancers
Yount, S., Cella, D. F., Webster, K., Heffernan, N., Chang, C., Odom, L., & van Gool, R. (2002) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(02)00422-0 · Cited by 88
New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication
Himmelsbach, K., Sauter, D., Baumert, T. F., Ludwig, L., Blum, H. E., & Hildt, E. (2009) · Gut · doi:10.1136/gut.2009.182212 · Cited by 87
The committee for revision of the Clinical Practice Guidelines for Hepatocellular Carcinoma
(2010) · Hepatology Research · doi:10.1111/j.1872-034x.2010.00650.x · Cited by 83
Guan, Z., Kang, Y. C., Chen, Z., Tsao, C., Qin, S., Kim, J. S., Burrock, K., Ju, Z., Voliotis, D., & Cheng, A. (2008) · Cited by 5
Self-citation
Cited by
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
AASLD guidelines for the treatment of hepatocellular carcinoma
Heimbach, J. K., Kulik, L. M., Finn, R. S., Sirlin, C. B., Abecassis, M. M., Roberts, L. R., Zhu, A. X., Murad, M. H., & Marrero, J. A. (2018) · Hepatology · doi:10.1002/hep.29086 · Cited by 4,070
Self-citationLlovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Self-citationEvidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
Bruix, J., Reig, M., & Sherman, M. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.12.041 · Cited by 1,694
Self-citationChallenges in liver cancer and possible treatment approaches
Anwanwan, D., Singh, S. K., Singh, S., Saikam, V., & Singh, R. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.188314 · Cited by 1,481
Metadata
- Authors
- Bruix, J., Raoul, J.-L., Sherman, M., Mazzaferro, V., Bolondi, L., Craxi, A., Galle, P. R., Santoro, A., Beaugrand, M., Sangiovanni, A., Porta, C., Gerken, G., Marrero, J. A., Nadel, A., Shan, M., Moscovici, M., Voliotis, D., & Llovet, J. M.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2012-10
- Volume
- 57
- Issue
- 4
- Pages
- 821-829
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2058887247
- Cited by
- 822
- References
- 42
- FWCI
- 33.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.